Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erdosteine - Edmond Pharma

Drug Profile

Erdosteine - Edmond Pharma

Alternative Names: ALT 09; Asdigan; Biopulmin; Dostin; Dostol; Ectrin; Edirel; Erdomed; Erdopect; Erdos; Erdostin; Erdotin; Esteclin; Fluidasa; Flusten; KW 9144; Mucoflux; Mucofor; Mucotec; Mucothera; RV 144; Secresolv; Tusselin and Theovix; Tussol; Vectrine

Latest Information Update: 28 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Edmond Pharma
  • Developer Alitair Pharmaceuticals Inc; Edmond Pharma
  • Class Anti-inflammatories; Antibronchitics; Expectorants; Small molecules; Thioglycolates; Thiophenes
  • Mechanism of Action Antioxidants; Glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bronchitis
  • Phase III Chronic obstructive pulmonary disease
  • No development reported Bronchiectasis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Bronchiectasis in USA (PO)
  • 18 Aug 2015 Phase II development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top